A Multicenter Open-Label Randomized Phase II Study of Osimertinib with and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve EGFR-Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE Trial).Xiuning Le,Jyoti D. Patel,Elaine Shum,Christina Baik,Rachel E. Sanborn,Catherine A. Shu,Chul Kim,Mary Jo Fidler,Richard Hall,Yasir Y. Elamin,Janet Tu,George Blumenschein,Jianjun Zhang,Don Gibbons,Carl Gay,Nisha A. Mohindra, Young Chae,Yanis Boumber,Joshua Sabari,Rafael Santana-Davila, Shane Rogosin,Benjamin Herzberg,Ben Creelan,Bruna Pellini,Tawee Tanvetyanon,Simon Heeke,Mike Hernandez,Jhanelle E. Gray,Andreas Saltos,John V. HeymachJOURNAL OF CLINICAL ONCOLOGY(2025)引用 1|浏览5AI 理解论文溯源树样例生成溯源树,研究论文发展脉络Chat Paper正在生成论文摘要